{"id":22817,"date":"2025-01-24T20:47:54","date_gmt":"2025-01-24T12:47:54","guid":{"rendered":"https:\/\/flcube.com\/?p=22817"},"modified":"2025-01-24T20:47:56","modified_gmt":"2025-01-24T12:47:56","slug":"conjustar-raises-rmb100-million-to-advance-x-drug-conjugates-pipeline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=22817","title":{"rendered":"ConjuStar Raises RMB100 Million to Advance X-Drug Conjugates Pipeline"},"content":{"rendered":"\n

ConjuStar, a specialist in X-Drug conjugates (XDCs) based in Tianjin, has reportedly raised RMB100 million (USD13.73 million) in a Pre-Series A+ financing round. The funding was led by Fosun Health Capital, with participation from Hengqin Venture Capital and Shenzhen Qianhailiyuan Investment. The proceeds will be used to accelerate core product clinical trials, develop new products, and advance the clinical translation of innovative XDC products.<\/p>\n\n\n\n

Funding Details and Strategic Use of Proceeds<\/strong>
The Pre-Series A+ financing round underscores ConjuStar’s commitment to advancing its differentiated product pipeline. The funds will be allocated towards ramping up clinical trials for its core products, enhancing R&D capabilities, and supporting the commercialization of its innovative XDCs. This strategic use of capital aims to solidify ConjuStar’s position in the rapidly growing field of targeted cancer therapies.<\/p>\n\n\n\n

Pipeline Highlights: SC-101 and SC-102<\/strong>
ConjuStar’s pipeline features a combination of collaborative and in-house development efforts. Its lead product, SC-101, is a Nectin-4-targeted peptide\u2013drug conjugate (PDC) currently undergoing Phase I clinical studies in the US and China. The product has demonstrated preliminary anti-tumor effects and strong safety profiles. The second product, SC-102, is another PDC targeting EphA2. Its clinical study, initiated in late 2023, has completed subject enrollment and dosing, positioning it for further evaluation and potential expansion.<\/p>\n\n\n\n

Implications for ConjuStar’s Future Growth<\/strong>
The successful completion of the Pre-Series A+ financing round highlights ConjuStar’s growing influence in the biotechnology sector. With a robust pipeline and strategic financial backing, the company is well-positioned to drive innovation in XDCs and deliver targeted therapies for unmet medical needs. The funding will support ConjuStar’s ongoing efforts to expand its global footprint and accelerate the development of next-generation cancer treatments.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

ConjuStar, a specialist in X-Drug conjugates (XDCs) based in Tianjin, has reportedly raised RMB100 million…<\/p>\n","protected":false},"author":1,"featured_media":22819,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[3173,20],"class_list":["post-22817","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-conjustar","tag-finance"],"yoast_head":"\nConjuStar Raises RMB100 Million to Advance X-Drug Conjugates Pipeline - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"ConjuStar, a specialist in X-Drug conjugates (XDCs) based in Tianjin, has reportedly raised RMB100 million (USD13.73 million) in a Pre-Series A+ financing round. The funding was led by Fosun Health Capital, with participation from Hengqin Venture Capital and Shenzhen Qianhailiyuan Investment. The proceeds will be used to accelerate core product clinical trials, develop new products, and advance the clinical translation of innovative XDC products.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=22817\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ConjuStar Raises RMB100 Million to Advance X-Drug Conjugates Pipeline\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=22817\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-24T12:47:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-24T12:47:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2411-png.avif\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"540\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22817#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22817\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"ConjuStar Raises RMB100 Million to Advance X-Drug Conjugates Pipeline\",\"datePublished\":\"2025-01-24T12:47:54+00:00\",\"dateModified\":\"2025-01-24T12:47:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22817\"},\"wordCount\":296,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22817#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/2411-png.avif\",\"keywords\":[\"ConjuStar\",\"Finance\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=22817#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22817\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=22817\",\"name\":\"ConjuStar Raises RMB100 Million to Advance X-Drug Conjugates Pipeline - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22817#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22817#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/2411-png.avif\",\"datePublished\":\"2025-01-24T12:47:54+00:00\",\"dateModified\":\"2025-01-24T12:47:56+00:00\",\"description\":\"ConjuStar, a specialist in X-Drug conjugates (XDCs) based in Tianjin, has reportedly raised RMB100 million (USD13.73 million) in a Pre-Series A+ financing round. The funding was led by Fosun Health Capital, with participation from Hengqin Venture Capital and Shenzhen Qianhailiyuan Investment. The proceeds will be used to accelerate core product clinical trials, develop new products, and advance the clinical translation of innovative XDC products.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22817#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=22817\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22817#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/2411-png.avif\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/2411-png.avif\",\"width\":1080,\"height\":540,\"caption\":\"ConjuStar Raises RMB100 Million to Advance X-Drug Conjugates Pipeline\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22817#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ConjuStar Raises RMB100 Million to Advance X-Drug Conjugates Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"ConjuStar Raises RMB100 Million to Advance X-Drug Conjugates Pipeline - Insight, China's Pharmaceutical Industry","description":"ConjuStar, a specialist in X-Drug conjugates (XDCs) based in Tianjin, has reportedly raised RMB100 million (USD13.73 million) in a Pre-Series A+ financing round. The funding was led by Fosun Health Capital, with participation from Hengqin Venture Capital and Shenzhen Qianhailiyuan Investment. The proceeds will be used to accelerate core product clinical trials, develop new products, and advance the clinical translation of innovative XDC products.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=22817","og_locale":"en_US","og_type":"article","og_title":"ConjuStar Raises RMB100 Million to Advance X-Drug Conjugates Pipeline","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=22817","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-01-24T12:47:54+00:00","article_modified_time":"2025-01-24T12:47:56+00:00","og_image":[{"width":1080,"height":540,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2411-png.avif","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=22817#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=22817"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"ConjuStar Raises RMB100 Million to Advance X-Drug Conjugates Pipeline","datePublished":"2025-01-24T12:47:54+00:00","dateModified":"2025-01-24T12:47:56+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=22817"},"wordCount":296,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=22817#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2411-png.avif","keywords":["ConjuStar","Finance"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=22817#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=22817","url":"https:\/\/flcube.com\/?p=22817","name":"ConjuStar Raises RMB100 Million to Advance X-Drug Conjugates Pipeline - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=22817#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=22817#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2411-png.avif","datePublished":"2025-01-24T12:47:54+00:00","dateModified":"2025-01-24T12:47:56+00:00","description":"ConjuStar, a specialist in X-Drug conjugates (XDCs) based in Tianjin, has reportedly raised RMB100 million (USD13.73 million) in a Pre-Series A+ financing round. The funding was led by Fosun Health Capital, with participation from Hengqin Venture Capital and Shenzhen Qianhailiyuan Investment. The proceeds will be used to accelerate core product clinical trials, develop new products, and advance the clinical translation of innovative XDC products.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=22817#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=22817"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=22817#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2411-png.avif","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2411-png.avif","width":1080,"height":540,"caption":"ConjuStar Raises RMB100 Million to Advance X-Drug Conjugates Pipeline"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=22817#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"ConjuStar Raises RMB100 Million to Advance X-Drug Conjugates Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2411-png.avif","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22817","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=22817"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22817\/revisions"}],"predecessor-version":[{"id":22820,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22817\/revisions\/22820"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/22819"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=22817"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=22817"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=22817"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}